Evidence map›Paper›PMID 39544417›Full record

ArticlePeerJ2024

Seroprevalence and silent infection rate during SARS-CoV-2 pandemic among children and adolescents in Western Pomerania: a multicenter, cross-sectional study-the COVIDKID study.

Marcus Vollmer, Daniela Kuthning, Jana Gramenz, Arevik Scholz, Robin Michael, Nico Wittmann, Udo Gesser, Christian Niesytto, Antje Vogler, Vanda Tuxhorn and 6 more

Abstract readMulticenter Study
In one paragraph

Article in PeerJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Marcus Vollmer *Institute of Bioinformatics, University Medicine Greifswald, Greifswald, Germany.
Daniela Kuthning *Pediatric Rheumatology, Department Pediatric and Adolescent Medicine, University Medicine Greifswald, Greifswald, Germany.
Jana GramenzPediatric Rheumatology, Department Pediatric and Adolescent Medicine, University Medicine Greifswald, Greifswald, Germany.
Arevik ScholzPediatric Rheumatology, Department Pediatric and Adolescent Medicine, University Medicine Greifswald, Greifswald, Germany.
Robin MichaelPediatric Rheumatology, Department Pediatric and Adolescent Medicine, University Medicine Greifswald, Greifswald, Germany.
Nico WittmannPediatric Rheumatology, Department Pediatric and Adolescent Medicine, University Medicine Greifswald, Greifswald, Germany.
Udo GesserChildren's Hospital, Sana Hospital Rügen, Bergen, Germany.
Christian NiesyttoDepartment of Pediatrics, AMEOS Hospital Anklam, Anklam, Germany.
Antje VoglerDepartment of Pediatrics, Asklepios Clinic Pasewalk, Pasewalk, Germany.
Vanda TuxhornDepartment of Pediatrics, Kreiskrankenhaus Demmin, Demmin, Germany.
Ute LenschowDepartment of Pediatrics, Helios Hanseklinikum Stralsund, Stralsund, Germany.
Anja LangePediatric Rheumatology, Department Pediatric and Adolescent Medicine, University Medicine Greifswald, Greifswald, Germany.
Kristina LinnemannPediatrics Outpatient Clinic, Greifswald, Germany.
Holger LodePediatric Hematology and Oncology, Department Pediatric and Adolescent Medicine, University Medicine Greifswald, Greifswald, Germany.
Lars KaderaliInstitute of Bioinformatics, University Medicine Greifswald, Greifswald, Germany.
Almut Meyer-BahlburgPediatric Rheumatology, Department Pediatric and Adolescent Medicine, University Medicine Greifswald, Greifswald, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Limited data on SARS-CoV-2 seroprevalence in rural areas of northern Germany necessitate comprehensive cohort studies. We aimed to evaluate the seroprevalence, silent infection (SI) rates and risk factors for infections among children and adolescents in Western Pomerania from December 2020 to August 2022. Methods: In this cross-sectional study, serum or plasma samples from children and adolescents (6 months to 17 years) were collected during routine blood draw. SARS-CoV-2 specific antibodies (S1 and nucleocapsid) and their neutralizing capacity were analyzed using commercially available enzyme-linked immunosorbent and neutralization assays. Socio-demographic data and information about SARS-CoV-2 infection or vaccination were obtained. Multivariable logistic regression was used to identify independent risk factors for SARS-CoV-2 infections and SI. Results: A total of 1,131 blood samples were included into the study. Overall, SARS-CoV-2 seroprevalence was 25.1%, strongly influenced by the pandemic course, predominant virus variants, age and approval of vaccination. SI rate was 5.4% (95%-CI [3.7%-6.8%]) among unvaccinated and undiagnosed children over the entire study period with highest rates among adolescents. Main risk factor despite the time at risk for silent infections was an infected household member (Odds ratio = 9.88, 95%-CI [4.23-22.9], Conclusions: We believe that the introduction of governmental measures and systematic test strategies in schools strongly impacted on the SI rate, as we suspect that asymptomatic cases have already been identified, resulting in surprisingly low SI identified in our study.

Indexed as

Antibodies, ViralCOVID-19SARS-CoV-2AdolescentAntibodies, NeutralizingAsymptomatic InfectionsChildChild, PreschoolCross-Sectional StudiesFemaleGermanyHumansInfantMaleRisk FactorsSeroepidemiologic StudiesAntibodies, NeutralizingAntibodies, ViralCovid-19IgA-S1IgG-S1NCP-IgGPandemicPediatricSARS-CoV-2SerologySeroprevalenceSilent infection

Identifiers

PMID39544417
PMCPMC11562825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.